Life Sciences

The days of blockbuster drugs, lofty revenues and regulatory clarity are gone. Is your organization prepared to implement the tools, processes and operational strategy required to survive, and even grow, over the next five years?

  • Kevin McCarty discusses company growth with The Chicago Sun-Times

    Industry: Banking & Credit Unions, Private Equity, Insurance, Healthcare, Life Sciences, Energy & Utilities, Manufacturing & Distribution, Retail
    Capability: Mergers & Acquisitions, Customer Experience, Operations Excellence, Advanced Analytics, Performance Services
    Date: February 26, 2015
  • Steve Sapletal featured on Benzinga

    Industry: Healthcare, Life Sciences
    Capability: Mergers & Acquisitions
    Date: February 6, 2015
  • Jeff Liter featured on Inbound Logistics

    Industry: Healthcare, Life Sciences
    Capability: Operations Excellence
    Date: February 2, 2015
    As hospitals begin transforming to adapt to new healthcare initiatives, they are easing the pain by restructuring and streamlining supply chain operations.
  • Jim Bedford featured in Genetic Engineering & Biotechnology News

    Industry: Life Sciences
    Capability: Operations Excellence
    Date: December 1, 2014
    In a recent Genetic Engineering & Biotechnology News article, West Monroe's Jim Bedford discusses Title VII of the U.S. Food and Drug Administration’s Safety and Innovation Act (FDASIA) of 2012.
  • The new and improved retail pharmacy experience

    Industry: Life Sciences, Retail
    Capability: Operations Excellence

    West Monroe Partners helped a large pharmacy chain redesign the way its pharmacy conducted business to remain competitive in the market. Lengthy wait times were hurting the customer experience and inefficient processes were costing a fortune. Without the capital to invest in a major overhaul of its infrastructure or new technology, the client was skeptical that it could achieve any meaningful improvements.

    This article summarizes the retail pharmacy chain's transformation.

  • As featured in Outsourced Pharma

    Industry: Life Sciences, Private Equity
    Date: May 20, 2014

    For major pharma companies, M&A is the new R&D, says Jim Bedford, director, Life Sciences practice, and John Hurley, director, Private Equity practice.

  • How to set expectations for the 2014 M&A landscape

    Industry: Banking & Credit Unions, Manufacturing & Distribution, Healthcare, Life Sciences, Private Equity
    Capability: Mergers & Acquisitions
    Date: March 13, 2014
    Globally 2013 wasn’t a knockout year for M&A. With just over 36,800 announced deals totaling $2.4 trillion (the slowest period for deal announcements since 2005 and for value since 2009), M&A activity remained somewhat underwhelming. West Monroe Partners took a deeper dive into the 2013 M&A landscape, examining deal stats through a strategic vs. financial buyer lens to figure out why last year played out as it did, and how to set expectations for 2014.
  • By Steve Sapletal as featured in BiotechBlog

    Industry: Life Sciences
    Capability: Mergers & Acquisitions
    Date: February 7, 2014
    Steve Sapletal, director in West Monroe Partners’ Minneapolis office, explains why large medical device companies may want to consider consolidating operations or selling non-strategic parts of their business in order to improve margins and profitability.
  • As featured in the Minneapolis/St. Paul Business Journal

    Industry: Life Sciences
    Capability: Mergers & Acquisitions
    Date: October 2, 2013
    West Monroe Partners acquired On Point Consulting, a Minneapolis-based firm specializing in merger integration solutions. The transaction combines West Monroe’s strength in the private equity segment of the M&A market with On Point’s solutions and expertise in the strategic/corporate buyer market, establishing one of the nation’s premier M&A advisory firms.
  • By Jim Bedford, as featured in Washington Healthcare News

    Industry: Life Sciences
    Capability: Customer Experience, Advanced Analytics
    Date: March 13, 2013
    Jim Bedford, Director of West Monroe's Life Sciences practice, discusses how the market for specialty drugs that provide therapy for certain chronic conditions has accelerated, and in turn, pharmaceutical organizations should focus on increasing patient adherence to capitalize on this growing sector.
Looking for a place where you can do your best work? Careers at WMP